Posted by Michael Wonder on 05 Mar 2026
Priovant announces FDA acceptance and priority review of new drug application for brepocitinib in dermatomyositis
3 March 2026 - Priovant Therapeutics today announced that the US FDA has accepted its new drug application for brepocitinib for the treatment of dermatomyositis and has granted the application priority review.
The FDA has assigned a PDUFA target action date in the third quarter of calendar year 2026.
The company expects to launch the drug in the US at the end of September 2026.
